Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR)
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Interleukin 6 (IL-6) signaling plays a role in inflammation, cancer, and senescence. Here, we identified soluble IL-6 receptor (sIL-6R) as a member of the senescence-associated secretory phenotype (SASP). Senescence-associated sIL-6R upregulation was mediated by mammalian target of rapamycin (mTOR). sIL-6R was mainly generated by a disintegrin and metalloprotease 10 (ADAM10)-dependent ectodomain shedding to enable IL-6 trans-signaling. In vivo, heterozygous PTEN-knockout mice exhibited higher mTOR activity and increased sIL-6R levels. Moreover, aberrant EGF receptor (EGFR) activation triggered IL-6 synthesis. In analogy to senescence, EGFR-induced activation of mTOR also induced IL-6R expression and sIL-6R generation. Hence, mTOR activation reprograms IL-6 non-responder cells into IL-6 responder cells. Our data suggest that mTOR serves as a central molecular switch to facilitate cellular IL-6 classic and trans-signaling via IL-6R upregulation with direct implications for cellular senescence and tumor development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
Self-citationNegative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Self-citationOncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
Kuilman, T., Michaloglou, C., Vredeveld, L. C. W., Douma, S., van Doorn, R., Desmet, C. J., Aarden, L. A., Mooi, W. J., & Peeper, D. S. (2008) · Cell · doi:10.1016/j.cell.2008.03.039 · Cited by 2,086 · cited 2×
“Furthermore, IL-6 has been reported to actively participate in the senescence process by reinforcing the senescence growth arrest in a positive feedback loop.(17) In addition to SASP formation, senescence is characterized by a persistent cell cycle arrest, which was first recognized to occur in fibroblasts after havin…”
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., Travis, W. D., Bornmann, W., Veach, D., Clarkson, B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31871 · Cited by 666
Rapamycin decelerates cellular senescence
Demidenko, Z. N., Zubova, S. G., Bukreeva, E. I., Pospelov, V. A., Pospelova, T. V., & Blagosklonny, M. V. (2009) · Cell Cycle · doi:10.4161/cc.8.12.8606 · Cited by 391
Matthews, V., Schuster, B., Schütze, S., Bussmeyer, I., Ludwig, A., Hundhausen, C., Sadowski, T., Saftig, P., Hartmann, D., Kallen, K.-J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210584200 · Cited by 390 · cited 1×
“A disintegrin and metalloprotease (ADAM) family members ADAM10 and ADAM17 have been identified as the main proteases responsible for sIL-6R generation.(6,7) Even though IL-6R expression limits IL-6 classic and transsignaling, the regulation of IL-6R expression is only incompletely understood.”
Self-citationYao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009472107 · Cited by 389
Blagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100443 · Cited by 251 · cited 1×
“Another hallmark of SIPS is the activation of mammalian target of rapamycin (mTOR), a serine-threonine kinase involved in the regulation of protein synthesis and cell growth, which might be related to the typically enlarged morphology of senescent cells.(19,20) Moreover, blocking the mTOR-complex mTORC1 by rapamycin o…”
Garbers, C., Jänner, N., Chalaris, A., Moss, M. L., Floss, D. M., Meyer, D., Koch-Nolte, F., Rose-John, S., & Scheller, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229393 · Cited by 201
Self-citationYun, U. J., Park, S. E., Jo, Y. S., Kim, J., & Shin, D. Y. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.003 · Cited by 69 · cited 1×
“It was suggested that the composition of the IL-6 target cell decides whether IL-6 acts as tumor suppressor or promoter.(36,37) Since gp130 is ubiquitously expressed, IL-6R expression determines whether a cell is responsive to classic signaling or trans-signaling.”
Cellular senescence: a double‐edged sword in the fight against cancer
Ohtani, N., Takahashi, A., Mann, D. J., & Hara, E. (2012) · Experimental Dermatology · doi:10.1111/j.1600-0625.2012.01493.x · Cited by 57 · cited 1×
“Cellular senescence is linked to age-associated diseases and inflammation and has recently been recognized as an important antitumor barrier.(16) The role of the SASP, however, in tumor progression remains unclear.”
Dittrich, A., Khouri, C., Sackett, S. D., Ehlting, C., Böhmer, O., Albrecht, U., Bode, J. G., Trautwein, C., & Schaper, F. (2012) · Hepatology · doi:10.1002/hep.24655 · Cited by 51 · cited 2×
“Long-term treatment with the synthetic glucocorticoid dexamethasone upregulated IL-6R mRNA and protein expression,(8-10) whereas short-term treatment interfered with the IL-6-induced SOCS3 negative feedback loop.(11) In T cells, IL-2 inhibits Th17 cell differentiation by blunting IL-6 responses via downregulation of t…”
Dulic, V. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-239-1_2 · Cited by 42
Cited by
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270
“Overexpression of additional oncogenes such as HER2, EGFR, and PI3K can also drive senescence in primary and tumor cells, and their signaling alters the SASP (14, 132).”
BackgroundCellular senescence and its effector programs
Salama, R., Sadaie, M., Hoare, M., & Narita, M. (2014) · Genes & Development · doi:10.1101/gad.235184.113 · Cited by 855
Interleukin-6 and its receptors: a highly regulated and dynamic system
Wolf, J., Rose-John, S., & Garbers, C. (2014) · Cytokine · doi:10.1016/j.cyto.2014.05.024 · Cited by 618
Self-citationCellular senescence as a potential mediator of COVID‐19 severity in the elderly
Nehme, J., Borghesan, M., Mackedenski, S., Bird, T. G., & Demaria, M. (2020) · Aging Cell · doi:10.1111/acel.13237 · Cited by 94
Non-cell autonomous effects of the senescence-associated secretory phenotype in cancer therapy.
Saleh, T., Tyutynuk-Massey, L., Cudjoe, E. K., Idowu, M. O., Landry, J. W., & Gewirtz, D. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00164 · Cited by 85
Metadata
- Authors
- Garbers, C., Kuck, F., Aparicio-Siegmund, S., Konzak, K., Kessenbrock, M., Sommerfeld, A., Häussinger, D., Lang, P., Brenner, D., Mak, T. W., Rose-John, S., Essmann, F., Schulze-Osthoff, K., Piekorz, R., & Scheller, J.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2013-09-18
- Volume
- 12
- Issue
- 21
- Pages
- 3421-3432
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W2074934443
- Cited by
- 64
- References
- 14
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.